“…Therefore, these B cells constitute a different phenotype to plasma cells that express CD138 (also termed Syndecan‐1, SDC1), which is a transmembrane protein acquired post‐GC (DiLillo et al , ; Nelson, ). Post‐GC plasma cells are important prognostic actors in diverse malignancies (Yip et al , ; Zhang et al , ; Bodoor et al , ; Mohammed et al , ; Berntsson et al , ; Lundgren et al , ), but there is a lack of clinicopathological studies examining late differentiated plasma cells in cHL (Tudor et al , ; Aldinucci et al , ; Vardhana & Younes, ; Hollander et al , ).…”